Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023.
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.
QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.
QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.
QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.
QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.
In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Stre
Qiagen (QGEN) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.53 per share a year ago.
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.
QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.
QIAGEN (QGEN) introduces API to give easier access to the QIAGEN Biomedical Knowledge Base.

Qiagen NV (QGEN) Q2 2023 Earnings Call Transcript

02:53pm, Wednesday, 09'th Aug 2023
Qiagen NV (NYSE:QGEN ) Q2 2023 Earnings Conference Call August 9, 2023 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - CEO Roland Sackers - CFO Confe
QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE